Compare CRWS & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRWS | AYTU |
|---|---|---|
| Founded | 1957 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6M | 25.7M |
| IPO Year | 1994 | 2015 |
| Metric | CRWS | AYTU |
|---|---|---|
| Price | $2.70 | $2.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 21.4K | ★ 44.0K |
| Earning Date | 02-11-2026 | 05-13-2026 |
| Dividend Yield | ★ 11.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $70,270,000.00 | $27,632,080.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 6.51 | ★ 277.47 |
| 52 Week Low | $2.35 | $0.95 |
| 52 Week High | $3.84 | $3.07 |
| Indicator | CRWS | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 39.70 | 59.90 |
| Support Level | $2.54 | $2.14 |
| Resistance Level | $2.94 | $2.82 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 24.22 | 87.50 |
Crown Crafts Inc operates in the infant and toddler products segment of the consumer products industry through its wholly-owned subsidiaries. The infant and toddler products segment consists of infant and toddler bedding, bibs, soft bath products, disposable products, and accessories. The company serves a diverse range of customers including mass merchants, mid-tier retailers, juvenile specialty stores, value channel stores, grocery and drug stores, restaurants, internet accounts, wholesale clubs, and internet-based retailers. The company's brands include NoJo, Neat Solutions, Sassy, and Carousel. Its products are marketed under a variety of company-owned trademarks, under trademarks licensed from others, and as private-label goods.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.